UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs; Express Scripts has decided it will cover Eli Lilly’s and Amgen’s migraine drugs and will not cover Teva Pharmaceutical's drug; black men are more likely to get and die from prostate cancer compared with white men, but they are underrepresented in prostate cancer research because of a general distrust of the healthcare system.
As part of CMS’ policy change that will allow Medicare Advantage plans to implement step therapy, UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs, according to The Center for Biosimilars®, a site from The American Journal of Managed Care®. Infliximab biosimilars Inflextra and Renflexis will be preferred over the reference, Remicade, and biosimilar epoetin alfa, sold as Retacrit, will be a preferred drug.
After price negotiations with Eli Lilly, Amgen, and Teva Pharmaceutical, Express Scripts has decided it will only cover Eli Lilly’s and Amgen’s migraine drugs. According to Reuters, the pharmacy benefit manager will limit the use of the migraine drugs to patients who are most likely to benefit. The 3 treatments work similarly, had similar success in reducing migraine frequency, and all have a list price of $575 a month. Amgen’s Aimovig was approved first in May 2018 and is listed as Express Scripts’ preferred treatment after patients try 2 older preventive therapies and triptan.
Despite the fact that black men are more likely to get and die from prostate cancer than white men, they are underrepresented in research because of distrust. NPR reported that focus groups of black men were unfamiliar with and less likely to pursue genomic testing, which could identify personalized approaches to monitoring and treating cancer. In general, the focus groups found a distrust in the healthcare system, stemming from ways African Americans have been treated by the medical system in the past.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen